NZ752893A - Synthetic chimeric poxviruses - Google Patents
Synthetic chimeric poxvirusesInfo
- Publication number
- NZ752893A NZ752893A NZ752893A NZ75289317A NZ752893A NZ 752893 A NZ752893 A NZ 752893A NZ 752893 A NZ752893 A NZ 752893A NZ 75289317 A NZ75289317 A NZ 75289317A NZ 752893 A NZ752893 A NZ 752893A
- Authority
- NZ
- New Zealand
- Prior art keywords
- synthetic chimeric
- chimeric poxviruses
- poxviruses
- synthetic
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416577P | 2016-11-02 | 2016-11-02 | |
| US201662434794P | 2016-12-15 | 2016-12-15 | |
| PCT/US2017/059782 WO2018085582A1 (en) | 2016-11-02 | 2017-11-02 | Synthetic chimeric poxviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ752893A true NZ752893A (en) | 2025-10-31 |
Family
ID=62075555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ752893A NZ752893A (en) | 2016-11-02 | 2017-11-02 | Synthetic chimeric poxviruses |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11345896B2 (enExample) |
| EP (1) | EP3535389A4 (enExample) |
| JP (3) | JP2019535311A (enExample) |
| CN (1) | CN110431228B (enExample) |
| AU (2) | AU2017353868C1 (enExample) |
| BR (1) | BR112019008781A2 (enExample) |
| CA (1) | CA3042694A1 (enExample) |
| IL (2) | IL319942A (enExample) |
| MX (1) | MX2019005102A (enExample) |
| NZ (1) | NZ752893A (enExample) |
| SG (1) | SG11201903893PA (enExample) |
| TW (2) | TW202528334A (enExample) |
| WO (1) | WO2018085582A1 (enExample) |
| ZA (3) | ZA201902868B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017353868C1 (en) | 2016-11-02 | 2024-06-06 | Tonix Pharma Limited | Synthetic chimeric poxviruses |
| US20180228921A1 (en) * | 2017-02-13 | 2018-08-16 | Excision Biotherapeutics, Inc. | Visualizing viral reservoirs and dissemination in vivo |
| MX2020011586A (es) * | 2018-05-02 | 2020-12-07 | David Evans | Virus vaccinia quimerico sintetico. |
| WO2020153734A1 (ko) * | 2019-01-25 | 2020-07-30 | 바이로큐어 주식회사 | 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| CN116348135A (zh) * | 2020-02-26 | 2023-06-27 | 通尼克斯制药有限公司 | 基于重组痘病毒的抗SARS-CoV-2病毒疫苗 |
| JP2024505274A (ja) | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
| WO2023168286A1 (en) | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| CN117264909B (zh) * | 2023-10-25 | 2024-11-26 | 深圳湾实验室 | 反式互补缺陷猴痘病毒及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2787577A (en) | 1953-12-01 | 1957-04-02 | Lilly Co Eli | Stable smallpox vaccine |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| CA2431349A1 (en) * | 2002-06-06 | 2003-12-06 | Xiao-Dan Yao | Method of producing a recombinant virus |
| US20070275010A1 (en) | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
| WO2006022215A1 (ja) | 2004-08-23 | 2006-03-02 | The Japan Health Sciences Foundation | SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用 |
| CN101020055B (zh) | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| US20090098529A1 (en) | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
| WO2009117030A2 (en) * | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| ES2768292T3 (es) | 2013-04-10 | 2020-06-22 | Tot Shanghai R&D Center Co Ltd | Cepas de virus vaccinia mutante, usos de estas y método para producirlas |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| CN115212301A (zh) | 2015-08-11 | 2022-10-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| EP3515419A4 (en) | 2016-09-21 | 2020-06-10 | Stephen H. Thorne | High mobility group box i mutant |
| AU2017353868C1 (en) | 2016-11-02 | 2024-06-06 | Tonix Pharma Limited | Synthetic chimeric poxviruses |
| ES2702618B2 (es) | 2017-09-04 | 2019-10-31 | Inst De Salud Carlos Iii | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. |
| MX2020011586A (es) | 2018-05-02 | 2020-12-07 | David Evans | Virus vaccinia quimerico sintetico. |
| EP3787681A4 (en) | 2018-05-02 | 2022-01-19 | Tonix Pharma Holdings Limited | Stem cells comprising synthetic chimeric vaccinia virus and methods of using them |
-
2017
- 2017-11-02 AU AU2017353868A patent/AU2017353868C1/en active Active
- 2017-11-02 MX MX2019005102A patent/MX2019005102A/es unknown
- 2017-11-02 JP JP2019545700A patent/JP2019535311A/ja active Pending
- 2017-11-02 BR BR112019008781-8A patent/BR112019008781A2/pt active Search and Examination
- 2017-11-02 US US15/802,189 patent/US11345896B2/en active Active
- 2017-11-02 IL IL319942A patent/IL319942A/en unknown
- 2017-11-02 CA CA3042694A patent/CA3042694A1/en active Pending
- 2017-11-02 WO PCT/US2017/059782 patent/WO2018085582A1/en not_active Ceased
- 2017-11-02 TW TW113144133A patent/TW202528334A/zh unknown
- 2017-11-02 SG SG11201903893PA patent/SG11201903893PA/en unknown
- 2017-11-02 NZ NZ752893A patent/NZ752893A/en unknown
- 2017-11-02 TW TW106137976A patent/TWI887191B/zh active
- 2017-11-02 CN CN201780078546.0A patent/CN110431228B/zh active Active
- 2017-11-02 IL IL266399A patent/IL266399B2/en unknown
- 2017-11-02 EP EP17868045.0A patent/EP3535389A4/en active Pending
-
2019
- 2019-05-07 ZA ZA2019/02868A patent/ZA201902868B/en unknown
-
2022
- 2022-05-06 ZA ZA2022/04981A patent/ZA202204981B/en unknown
- 2022-05-27 US US17/827,320 patent/US12365879B2/en active Active
- 2022-09-02 JP JP2022140113A patent/JP2022164900A/ja not_active Withdrawn
-
2024
- 2024-02-15 AU AU2024200997A patent/AU2024200997A1/en not_active Abandoned
- 2024-05-02 ZA ZA2024/03393A patent/ZA202403393B/en unknown
- 2024-06-10 JP JP2024093677A patent/JP2024107257A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL266399B1 (en) | 2025-05-01 |
| AU2017353868A1 (en) | 2019-05-16 |
| AU2017353868B2 (en) | 2024-02-29 |
| IL266399A (en) | 2019-06-30 |
| ZA202204981B (en) | 2024-09-25 |
| ZA202403393B (en) | 2025-08-27 |
| TWI887191B (zh) | 2025-06-21 |
| JP2019535311A (ja) | 2019-12-12 |
| US20180251736A1 (en) | 2018-09-06 |
| ZA201902868B (en) | 2022-12-21 |
| JP2022164900A (ja) | 2022-10-27 |
| CA3042694A1 (en) | 2018-05-11 |
| IL266399B2 (en) | 2025-09-01 |
| TW202528334A (zh) | 2025-07-16 |
| IL319942A (en) | 2025-05-01 |
| AU2017353868C1 (en) | 2024-06-06 |
| AU2024200997A1 (en) | 2024-03-07 |
| TW201819400A (zh) | 2018-06-01 |
| US12365879B2 (en) | 2025-07-22 |
| EP3535389A4 (en) | 2020-06-03 |
| JP2024107257A (ja) | 2024-08-08 |
| CN110431228B (zh) | 2024-04-02 |
| MX2019005102A (es) | 2019-10-30 |
| SG11201903893PA (en) | 2019-05-30 |
| EP3535389A1 (en) | 2019-09-11 |
| US11345896B2 (en) | 2022-05-31 |
| WO2018085582A1 (en) | 2018-05-11 |
| BR112019008781A2 (pt) | 2019-07-16 |
| US20230002741A1 (en) | 2023-01-05 |
| CN110431228A (zh) | 2019-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202403393B (en) | Synthetic chimeric poxviruses | |
| ZA201802657B (en) | Crystal forms of beta-nicotinamide mononucleotide | |
| MX2020011586A (es) | Virus vaccinia quimerico sintetico. | |
| CA3024448C (en) | Modulatory polynucleotides | |
| PH12017500858A1 (en) | Mocrocyclic peptides useful as immunomodulators | |
| MX2023008693A (es) | Polinucleotidos moduladores. | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| MY191581A (en) | Anti-pd-1 antibodies | |
| MX2021001053A (es) | Vacunas contra virus de la influenza y sus usos. | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| MY191539A (en) | Streptococcal vaccine | |
| MX387421B (es) | Producción de virus en huevos aviares. | |
| ZA201701000B (en) | Attenuated bovine coronavirus and related vaccines | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| MX2018005462A (es) | Composiciones inmunogénicas de rsv quimérico y métodos de uso. | |
| EA201792512A1 (ru) | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник | |
| IN2014CH00840A (enExample) | ||
| MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| JOP20200126A1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد | |
| MX2020002793A (es) | Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados. | |
| NZ721832A (en) | Solid forms of tenofovir |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: TONIX PHARMA LIMITED, IE Effective date: 20250416 |